Edition:
United Kingdom

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

21.85EUR
22 Jul 2019
Change (% chg)

€-0.15 (-0.68%)
Prev Close
€22.00
Open
€22.00
Day's High
€22.00
Day's Low
€21.85
Volume
68
Avg. Vol
16,404
52-wk High
€25.00
52-wk Low
€19.82

Latest Key Developments (Source: Significant Developments)

Biotest Q1 Loss After Tax From Continuing Operations At EUR -1.2 Mln
Tuesday, 7 May 2019 

May 7 (Reuters) - BIOTEST AG ::REACHES REVENUES OF EUR 77.5 MILLION IN THE FIRST QUARTER 2019.Q1 LOSS AFTER TAX FROM CONTINUING OPERATIONS -1.2 MILLION EUR VERSUS -8.1 MILLION EUR LOSS YEAR AGO.Q1 EBIT LOSS FROM CONTINUING OPERATIONS -9.9 MILLION EUR VERSUS -3.0 MILLION EUR LOSS YEAR AGO.Q1 REVENUE 77.5 MILLION EUR.OUTLOOK 2019: EBIT OF EUR -15 TO -35 MILLION COULD THEN BE EXPECTED.OUTLOOK 2019: EBIT OF EUR -5 TO +5 MILLION IS FORECAST IF PARTNERING AGREEMENTS ARE SUCCESSFULLY CONCLUDED.  Full Article

Biotest: Approval For Double Concentrated Haemoctin SDH For Improved Haemophilia A Treatment In Europe
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Biotest AG ::RECEIVES APPROVAL FOR DOUBLE CONCENTRATED HAEMOCTIN(R) SDH FOR IMPROVED HAEMOPHILIA A TREATMENT IN EUROPE.  Full Article

Biotest 9-mth Result After Tax Turns To Profit
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - Biotest AG ::9M EBIT 5.1 MILLION EUR.9M PROFIT AFTER TAX 190.9 MILLION EUR VERSUS -22.2 MILLION EUR LOSS YEAR AGO.INCREASES SALES IN FIRST NINE MONTHS OF 2018 TO EUR 289.6 MILLION.FOR FY ANTICIPATES EBIT OF CONTINUING OPERATIONS IN RANGE OF EUR 10 TO 12 MILLION.FOR 2018 EXPECTS SALES OF CONTINUING OPERATIONS TO INCREASE BY A MID-SINGLE-DIGIT PERCENTAGE.  Full Article

Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - BIOTEST AG ::DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT GUIDANCE.FY REVENUE 378.1 MILLION EUR.MAIN REASON FOR DECLINE IN REVENUE WAS RECALL OF HUMAN ALBUMIN.FY EBIT GUIDANCE WAS REACHED WITH EUR 18 MILLION.2017 REVENUE OF EUR 378.1 MILLION IN CONTINUING OPERATIONS, COMPARED TO EUR 408.0 MILLION IN PREVIOUS YEAR​.ONE-OFF EXPENSES IN AMOUNT OF EUR 37.7 MILLION HAD A NEGATIVE IMPACT ON EBIT OF CONTINUING OPERATIONS.EBIT IN CONTINUING OPERATIONS AMOUNTED TO EUR -9.3 MILLION IN 2017 AFTER EUR 35.2 MILLION IN PREVIOUS YEAR.  Full Article

Biotest says Tiancheng to enter into domination agreement
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Biotest Ag ::DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG.SAYS ‍TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG​.SAYS ‍TIANCHENG HAS ASKED TO ENTER INTO NEGOTIATIONS​.SAYS ‍EXPECTS THAT CASH COMPENSATION AND GUARANTEED DIVIDEND FOR MINORITY SHAREHOLDERS OF BIOTEST AG WILL BE DETERMINED IN ACCORDANCE WITH STATUTORY REQUIREMENTS AND ON BASIS OF A PENDING EVALUATION OF COMPANY​.SAYS ‍INTENDED DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT REQUIRES APPROVAL OF GENERAL SHAREHOLDERS' MEETING OF BIOTEST AG​.  Full Article

Biotest: Creat Takeover Of Biotest Closed
Wednesday, 31 Jan 2018 

Jan 31 (Reuters) - BIOTEST AG ::DGAP-NEWS: BIOTEST AG: CREAT TAKEOVER OF BIOTEST CLOSED.TRANSFER OF TENDERED SHARES COMPLETED.MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST.  Full Article

Biotest 9-mth revenue at EUR 377.8 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BIOTEST AG ::DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017.9M REVENUE 377.8 MILLION EUR.‍PAUL-EHRLICH INSTITUTE APPROVES PHASE III TRIAL IN INDICATION OF ACQUIRED FIBRINOGEN DEFICIENCY​.‍EBIT OF CONTINUING OPERATIONS TOTALED EUR -15.7 MILLION IN FIRST THREE QUARTERS OF 2017 AFTER EUR 47.5 MILLION​.9-MONTH ‍EARNINGS AFTER TAXES OF CONTINUING OPERATIONS OF EUR -22.7 MILLION VERSUS EUR 13.3 MILLION YEAR AGO​.  Full Article

Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BIOTEST AG ::‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​.‍TIANCHENG WITHDRAWAL OF APPLICATION OF TRANSACTION FROM CFIUS AND REFILING​.BIOTEST - ‍TIANCHENG AND BIOTEST TO WITHDRAW THEIR NOTICE AND TO REFILE NEW APPLICATION WITH REQUEST FOR EXPEDITED REVIEW PERIOD​.  Full Article

Curetis partners with Biotest to support academic PEPPER Pentaglobin Peritonitis trial
Tuesday, 15 Aug 2017 

Aug 15 (Reuters) - CURETIS NV ::CURETIS PARTNERS WITH BIOTEST <<>> TO SUPPORT ACADEMIC PEPPER PENTAGLOBIN® PERITONITIS TRIAL WITH UNYVERO IAI APPLICATION.‍TO PROVIDE TESTING SERVICES FOR DIFFERENT SAMPLES FROM UP TO 200 PATIENTS WITH UNYVERO IAI APPLICATION.  Full Article

Biotest H1 result swings to loss of 17.8 million euros
Monday, 14 Aug 2017 

Aug 14 (Reuters) - BIOTEST AG ::H1 REVENUE FROM CONTINUING OPERATIONS FELL 11 PERCENT TO 247.1 MILLION EUR.H1 LOSS AFTER TAX -17.8 MILLION EUR VERSUS 7.7 MILLION EUR PROFIT YEAR AGO.‍EBIT OF CONTINUING OPERATIONS AMOUNTED TO EUR -20.2 MILLION IN FIRST HALF OF 2017 COMPARED TO PREVIOUS YEAR'S FIGURE OF EUR 33.3 MILLION​.‍TOTAL EARNINGS AFTER TAXES (EAT) AMOUNTED TO EUR -17.8 MILLION IN FIRST HALF OF 2017 (SAME PERIOD OF PREVIOUS YEAR: EUR 7.7 MILLION)​.NOW FORECASTING SALES AT PREVIOUS YEAR'S LEVEL FOR CONTINUING OPERATIONS IN 2017, AFTER PREVIOUS FORECAST LOW SINGLE-DIGIT PERCENT INCREASE IN SALES​.FY EBIT F'CAST FOR CONTINUING OPERATIONS OF EUR 46-48 MILLION AND CASH FLOW FROM OPERATING ACTIVITIES OF APPROX EUR 40 MILLION HAVE BEEN REDUCED BY AROUND EUR 25 MILLION TO EUR 30 MILLION​.  Full Article